Efficacy of Pancragen Peptide in Elderly Patients With Type 2 Diabetes Mellitus

Abstract

The paper shows that in elderly patients with uncompensated diabetes 2 types of course application of the drug Pankragen (RF Patent № 2242241) on Against the background of constant doses of glibenclamide leads to a significant decrease in plasma glucose levels on an empty stomach and 2 hours after the oral glucose tolerance test. An additional sugar -free effect is preserved two weeks after the cancellation of the pankration in 60 % of patients who continued to takeglibenclamide in previous doses. Pankochen has an additional sugar -free effect in patients with high initial resistance to insulinAnd hyperinSulinemia. Under the influence of the peptide preparation, the index decreases Homa insulin resistance. Any side effects or undesirable changes in laboratory indicators associated with the receptionObserving. Pankochen is shown to an elderly patient with an uncompensated course of type 2 diabetes with insufficient effectiveness of therapeuticGlibenclamide dosages.

The Correction of Melatonin-Producing Function Violations of Pineal Gland in Elderly People With Substitutive Doses of Melatonin and Epiphysis Peptide Drugs

“…Як було показано в експериментi на тваринах i при обстеженнi людей похилого вiку, при старiннi розвивається функцiональна недостатнiсть епiфiза, яка проявляється зниженням нiчного пiку концентрацiї мелатонiну в плазмi кровi та нiчної екскрецiї з сечею його основного метаболiту 6-гiдрокси-мелатонiнсульфату (6-ГМС). При цьому знижується середньодобова i, особливо, нiчна секрецiя мелатонiну, тобто порушується добовий ритм продукцiї гормону [3][4][5][6].…”